Calcium carbimide

Calcium carbimide
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	N07BB02 (WHO) ;
Identifiers
	IUPAC name calcium 2-hydroxypropane-1,2,3-tricarboxylate; methylcyanamide;
CAS Number	8013-88-5 ;
PubChem CID	6335910;
ChemSpider	21106422 ;
UNII	ZLR270912W;
ChEMBL	ChEMBL2106095 ;
Chemical and physical data
Formula	C6H8O7.CH2N2.Ca
Molar mass	288.268 g/mol
3D model (JSmol)	Interactive image;
	SMILES [Ca+2].O=C([O-])CC(O)(CC(=O)O)C([O-])=O.N#CNC;
	InChI InChI=1S/C6H8O7.C2H4N2.Ca/c7-3(8)1-6(13,5(11)12)2-4(9)10;1-4-2-3;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);4H,1H3;/q;;+2/p-2 ; Key:ZZOBQLACMMNMCT-UHFFFAOYSA-L ;
	(what is this?) (verify)

Calcium carbimide, sold as the citrate salt under the trade name Temposil, is an alcohol sensitizing agent. Its effects are similar to the drug disulfiram (Antabuse) in that it interferes with the normal metabolism of alcohol by preventing the breakdown of the metabolic byproduct acetaldehyde. The result is that when alcohol is consumed by users of calcium carbimide, they experience severe reactions which include symptoms such as sweating, difficulty breathing, rapid heartbeat, rash, nausea and vomiting, and headache.

A recent 9-year study found that incorporation of supervised carbimide and the similar drug, disulfiram, into a comprehensive treatment program resulted in an abstinence rate of over 50%.^[1]

References

^ Krampe H, Stawicki S, Wagner T; et al. (January 2006). "Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome". Alcoholism, clinical and experimental research. 30 (1): 86–95. doi:10.1111/j.1530-0277.2006.00013.x. ISSN 0145-6008. PMID 16433735. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] Krampe H, Stawicki S, Wagner T; et al. (January 2006). "Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome". Alcoholism, clinical and experimental research. 30 (1): 86–95. doi:10.1111/j.1530-0277.2006.00013.x. ISSN 0145-6008. PMID 16433735. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)

[1]

v t e Treatment of drug dependence (N07B)
Nicotine dependence	Bupropion^# Cytisine Lobeline Mecamylamine Varenicline AATooltip Adrenergic agonist (Clonidine)
Alcohol dependence	AD inhibitor (Disulfiram Calcium carbimide Hydrogen cyanamide) Acamprosate Opioid antagonists Naltrexone Nalmefene Topiramate AATooltip Adrenergic agonist (Clonidine) Baclofen Phenibut
Opioid dependence	AATooltip Adrenergic agonist (Clonidine Lofexidine) Ibogaine Opioids Buprenorphine (+naloxone) Levacetylmethadol Methadone Dihydrocodeine Dihydroetorphine Hydromorphone (extended-release) Morphine (extended-release) Opioid antagonists (Naltrexone Nalmefene)
Benzodiazepine dependence	AATooltip Adrenergic agonist (Clonidine) Benzodiazepines (Diazepam Lorazepam Chlordiazepoxide Oxazepam) Barbiturates (Phenobarbital)

See also

References